Former Pfizer Executives Distance Themselves from Starboard's Campaign

In an unexpected turn of events, former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio have stepped away from Starboard Value's activist campaign against the pharmaceutical giant. This development comes just days after Starboard revealed its stake in Pfizer and plans to push for changes in the company's strategy. Read and D'Amelio, who were initially supportive of Starboard's efforts, released a joint statement via an investment bank, expressing their confidence in Pfizer's current board and management.

The decision by Read and D'Amelio to distance themselves from Starboard's campaign is highly unusual, as it is rare for executives to join and then leave an activist's effort. The about-face raises questions about the potential impact on Starboard's strategy and Pfizer's future. It also leaves the door open for Pfizer's board and management to strengthen their position against Starboard's campaign.


The absence of Read and D'Amelio's support may hinder Starboard's ability to rally shareholder support for its campaign. However, Starboard, led by Jeff Smith, is known for its tenacity and has successfully mounted campaigns at other companies, such as Autodesk and Salesforce. It remains to be seen how Starboard will adapt its strategy in light of this development.


Pfizer's board and management may view the departure of these former executives as a vote of confidence in their leadership. They could use this opportunity to reinforce their commitment to the company's current strategy and reassure shareholders. The outcome of Starboard's campaign will depend on various factors, including the response from Pfizer's board and management, the support of other shareholders, and the broader market conditions.

In conclusion, the decision by former Pfizer executives Ian Read and Frank D'Amelio to step away from Starboard's activist campaign adds a new dimension to the ongoing battle for control at the pharmaceutical giant. As the situation unfolds, investors and stakeholders will be watching closely to see how this development impacts the future of Pfizer and the broader pharmaceutical industry.